S1. Used and retrieved sequences for EGF-CFC in different organisms. \* this study.

SPECIES	ACCESION NUMBER
Novocrania anomala EGF_CFC_mRNA	OP006211*
Patella vulgata EGF_CFC_1_mRNA	OP006209*
Patella vulgata EGF_CFC_2_mRNA	OP006210*
Lottia_gigantea_EGF_CFC	Prot ID 233075
Crepidula fornicata EGF_CFC_mRNA	OP006207*
Owenia fusiformis EGF_CFC_mRNA	OP006212*
Biomphalaria glabrata EGF_CFC_mRNA	OP006208*
Spirobranchus lamarckii EGF_CFC_mRNA	OP006213*
Branchiostoma_floridae_EGF_CFC	XM_002207525
Gallus_gallus_EGF_CFC	NP_990031
Monodelphis_domestica_EG_CFC	ENSMODP000003767
Danio_rerio_Oep	NP571167
Takifugu_rubripes_Oep	ENSTRUP00000013088
Xenopus_laevis_Xcr1	AAA83569
Xenopus_laevis_Xcr2	CAI15753
Xenopus_laevis_Xcr3	NP_001089135
Xenopus_tropicalis_Xcr1	ENSXETP00000020142
Xenopus_tropicalis_Xcr2	ENSXETP00000020145
Xenopus_tropicalis_Xcr3	NP_001078829
Homo_sapiens_Crc	NP_115934
Mus_musculus_Crc	NP_031711
Loxodonta_africana_Crc	ENSLAFP00000005045
Erinaceus_europaeus_Crc	ENSETEP00000015228
Mus_musculus_Cro	AAH52646
Loxodonta_africana_Cro	ENSLAFP00000007663
Erinaceus_europaeus_Cro	ENSEEUP00000004109
Homo_sapiens_Cro	NP_003203
Homo_sapiens_Cro3	P51864
Strongylocentrotus_purpuratus_EGF_CFC	XP_787941.2
Lytechinus_variegatus_EGF_CFC	XP_041475421.1
Asterias_rubens_EGF_CFC	XP_033636697.1
Acanthaster_planci_EGF_CFC	XP_022097255.1
Patiria_miniata_EGF_CFC	XP_038069138.1
Ptychodera_flava_EGF_CFC	AJS19017.1
Saccoglossus_kowalevskii_EGF_CFC	NP_001161522.1



**S2.** The addition of RHAct-A leads to the inactivation of the Nodal pathway, presumably by competition with the ligand NodalB for the receptors. A) Transcription of *Pitx* is activated by the signaling cascades transduced the NodalB binding to the receptor cluster. In preveliger larvae, *Pitx* is symmetrically expressed in the anterior region and is also asymmetrical on the right side (fig. 2C). B) RHAct-A presumably prevents NodalB from binding the receptor cluster, due to direct competition. Subsequently, no asymmetrical *Pitx* expression is promoted, as showed by *Pitx* whole mount *in situ* hybridization in treated embryos (fig. 3D); though such silencing only occurs in the asymmetrical territories, while its symmetrical activation signals remain unaffected. Scale corresponds to 30 µm.



**S3.** Two alternative hypotheses for the origin of the amino acid change in the position T88 (human) of the ancestral EGF-CFC sequences in Deuterostomia. A) Hypothesis 1 (orange): The change to a threonine occurred in the common ancestor of all deuterostomes and was subsequently modified in the stem lineages that lead to echinozoans and hemichordates (changing to an isoleucine). B) Hypothesis 2 (green): The change to a threonine occurred in the common ancestor of chordates and the presence of a threonine in asterozoans is the result of convergent evolution. The amino acid identity in position T88 (human) is shown in parenthesis for each main group of deuterostomes: I, isoleucine; T, threonine.

**S4. Orthology analysis details.** Orthology was determined by alignment of these candidates with the validated sequences from vertebrate representatives. Alignments were performed using ClustalX v2.1 (Larkin *et al.*, 2007), followed by refinement by eye, and trimmed in Mesquite v2.75 OSX (Maddison & Maddison, 2011) in order to select their main protein domains. All the potential EGF-CFC sequences retrieved in our searches contained the specific domains (EGF-like domain, CFC domain) (Fig 1E). The alignments of all these sequences were subject to coalescent-based Bayesian Inference (BI) phylogenetic analyses implemented in the software BEAST 1.8.3 (Drummond *et al.*, 2012). The WAG model (Whelan & Goldman, 2001) was selected as the best-fit model of protein evolution using ProtTest (Abascal *et al.*, 2005). Tree shown is the result of Bayesian analysis, run for 25,000,000 generations, and analyses run until the s.d. of split frequencies was below 0.01, with the first 25% of sampled trees discarded as 'burn-in'.

S5. Primers used to clone the different fragments and complete CDS of *C. fornicata egf-cfc* and NodalB, and *D. rerio oep* 

PRIMER NAME	SEQUENCE
Criptocrepi-F-2	GGGCGAAGGCAGGATGTAACTT
Criptocrepi-F-2-IN	ATGTAACTTGTGTCGCTGCTTTG
CriptoCrepi-F3	GAAGTTTTACGGGCGCTACTGTGA
CriptoCrepi-F3-in	GCGCTACTGTGAGTATGAGCTGTC
CriptoCrepi-R3	TGACACGAGTGTCCATGAGGTCCA
CriptoCrepi-R3-in	CCATGAGGTCCAGAGTATCGTAAC
CriptoCrepi-R4	TTCTATTATGTATACGCATATTCC
CriptoCrepi-R4-in	TACGCATATTCCACTTCCAGTTTT
CriptoCrepi-R5	AGTTATGTGCATAGGCAGCATGGT
CriptoCrepi-R5-in	ATCTTTAAGTGTAGTTATGTGCAT
CriptoCrepi-F4	GACGTGTCGTCTGTCAGGGGTCTG
CriptoCrepi-F4-in	GTCAGGGGTCTGATCACGCTGGTC
CriptoCrepiBamHI-F	gggggatccATGGACGTGTCGTCTGTCAGGGGT
CriptoCrepiXhoI-R	CCCCTCGAGTGACACGAGTGTCCATGAGGTCCA
CR_L56T_F	GTCGTGCTGCCTGAACGGGGGGCACGTGTGTGCTGG
CR_L56T_R	TTGGAGGGTCTAGGGTTCAAGTCTCCCAGCCTG
CR_L56A_F	GTCGTGCTGCCTGAACGGGGGGCGCGTGTGTGCTG
CR_L56A_R	TTGGAGGGTCTAGGGTTCAAGTCTCCCAGCGTCTTC
CR_DEGF_F	AAGCCATGTGGTCCTGTGCCTCATGGCAGCTGGGC
CR_DEGF_R	GGGTTTGGGGTTCAAGTCTCCCAGCGTCTTCTTCG
NodalCrepi_F2	GTGGGTCATAATAAACACAGGTCT
NodalCrepi_F2_in	AAACACAGGTCTCGTGACAAGAGA
NodalCrepi_R2	CAGCTATCATATTTTCGTGGTGGC
NodalCrepi_R2_in	TTTCGTGGTGGCGAACCACAATCT
NodalB Crepi_F3	ACTTGACCGTGGTAGGTCAAGACT
NodalB Crepi_F3_in	TAGGTCAAGACTCAGATGTCCAGT
NodalB Crepi_R3	CTACTGGTCCTAGAGGTAGTAGAT
NodalB Crepi_R3_in	GAGGTAGTAGATGCTCTCTTGTCA
NodalB_Crepi_DCS_F	GCCCCCAAGCACGAAAAATGCCAGATGTAC
NodalB_Crepi_DCS_	ACGTTTAGATTCCCTACTGGTCCTAGAGG
NodalB Crepi_F4	CACAAGAGGTGATGTCTCACAGAG
NodalB Crepi_F4in	TGTCTCACAGAGAGGTCTCTAGGT
NodalB Crepi_R4	GTGCACACATGGACGACAATCACC
NodalB Crepi_R4in	ACGACAATCACCTACACCCACACT
NodalB _Crepi_Ecol_F	GGGGAATTCATGCCATTATTTTCGGCAGCC
NodalB_Crepi_Sall_R	CCCGTCGACCCTACACCCACACTCATCAGC
Oep_ZF_F	GGCCAGCGGAATGACGAGTCAAC
Oep_ZF_R	AAACTCATTTACAGCAGGCGGTG
Oep_ZF_BI_F	gggggatccATGACGAGTCAACTGTTCGGGT
Oep_ZF_SI_R	CCCGTCGACCAGCAGGCGGTGTAAAATAAAAGTG

**S6.** Construct details and microinjection protocol. The *nodal2-* $\Delta$ *CS* construct lacks 13 amino acids [<u>**RKNR**</u>NNKKK<u>**RWYR**</u>], which potentially includes the cleavage site domain. This fragment contains two potential sites, according to the consensus RXXR. A previous publication suggests a redundancy between two close sites, hence a deletion containing both was designed (Eimon & Harland, 2002). The EGF-CFC\_ $\Delta$ EGF construct lacks 29 amino acids corresponding to the EGF-like domain

[CCLNGGLCVLDSFCHCPKKFYGRYCEYKP]. A mutation was introduced to the EGF-CFC\_L56T construct, changing the Leucine at position 56 (bolded) inside the EGF-like domain to Threonine [CCLNGGLCVLDSFCHCPKKFYGRYCEYKP]. The mRNA was prepared by PCR amplification of the construct, with SP6 and T3 primers and Phusion High Fidelity DNA polymerase (New England, BioLabs). The purified product was used as a template for the transcription reaction using the mMessage mMachine SP6 RNA transcription kit (AM1340, Ambion, Austin, TX), as previously described (Henry *et al.*, 2010). The same protocol was followed for *oep* mRNA, amplified from cDNA generated from 24 hours post-fertilization *D. rerio* embryos. Fertilized eggs of *C. fornicata* and *D. rerio* were pressure microinjected. The device used for the experiments on *C. fornicata* is described in Truchado-Garcia *et al.*, 2018 (Truchado-Garcia M, Harland RM, Abrams MJ, unpublished method, <u>https://www.biorxiv.org/content/10.1101/376657v1.full</u>), and a semidry technique (pretri-dish and a glass slide) was used to hold zebrafish embryos.